Carl Zeiss Meditec reports 7.3% revenue growth in Q2
Carl Zeiss Meditec reported an increase in revenue to €673.7 million, corresponding to a growth of 7.3% after adjusting for exchange rates, according to a company press release.
Taking into account the negative impact from currency translation effects present in previous quarters, the company’s revenue increased by 3.8% compared with the same period in 2013.
Translation effects also impacted growth in earnings before interest and taxes (EBIT; €92.1 million) and the EBIT margin (13.7%); however, the 9-month report signified neutral results from currency-hedging transactions, equating to 13.5% reductions in earnings per share, according to the release.
The Surgical Ophthalmology SBU recorded the strongest revenue growth (22%), due to the acquisition of Aaren Scientific. Microsurgery SBU revenues increased only slightly, with surgical microscopes and visualization solutions increasing by 5.9%, according to the release.
Ophthalmic Systems SBU was able to keep its revenues at almost the previous year’s level, the company reported. Adjustments for currency translations led to a 3.6% growth, with demand for innovative lasers for refractive surgery.